The phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks
The INSPIRE-1 and INSPIRE-2 trials are Phase 3 studies assessing the efficacy and safety of tildrakizumab 100 mg (ILUMYA) in adults with active psoriatic arthritis (PsA)
Clinical data showing unprecedented remission rates in newly diagnosed AML patients support advancing ICT01 into pivotal trials
This achievement underscores our unwavering commitment to upholding the highest standards of quality, safety, and regulatory compliance
The company’s largest center for medical device applications, serving the entire Asian market
To streamline complex medical writing workflows with GenAI
IGI partners with AbbVie and grants exclusive rights to globally develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China
The UK authorization is based on positive results from the Phase III OASIS-1, -2, and -3 trials
Lupin and Zentiva sign license and supply agreement for commercializing Certolizumab
The submission is based on data from the STEP UP and STEP UP T2D clinical trials
Subscribe To Our Newsletter & Stay Updated
